Navigation Links
Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint
Date:11/1/2007

Preliminary Analysis Demonstrates a 20-Meter Improvement in Six-Minute Walk

Distance (p<0.0006) Conference Call to be Held at 9:00 a.m. Eastern Time on November 1, 2007

SILVER SPRING, Md., Nov. 1 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary, Lung Rx, Inc., announced today the completion of their TRIUMPH-1 Phase 3 trial of Viveta, an inhaled formulation of treprostinil, in pulmonary arterial hypertension (PAH). Preliminary analysis demonstrates that the trial has robustly met its primary endpoint.

The TRIUMPH-1 (TReprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension) trial was a randomized, double-blind, placebo-controlled trial of patients with severe PAH, a chronic, life- threatening illness. The study population consisted of 235 patients who were optimized on an approved oral therapy for PAH, either bosentan (Tracleer), an endothelin receptor antagonist, or sildenafil (Revatio), a phosphodiesterase-5 inhibitor. In addition to one of these oral therapies, patients were administered Viveta or placebo in four daily inhalation sessions with a maximum dose of 45 micrograms per session over the course of the 12-week trial. The majority (~98%) of patients were New York Heart Association (NYHA) Class III of varied etiologies, including idiopathic or familial PAH (~55%), collagen vascular disease associated PAH (~35%), and PAH associated with HIV, anorexigens or other associated conditions (~10%). Mean baseline walk distance was approximately 350 meters.

The primary efficacy endpoint of the trial was the change in six-minute walk (6MW) distance at 12 weeks measured at peak exposure, def
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Man against HIV – new vaccine ready for human trials
2. FDA approves Phase 0 trial which tests experimental drugs on humans
3. Male contraceptive in trial
4. How do patients benefit of clinical trials
5. Glenmark’s new molecule to go through trial
6. Clinical trials need to be more frank
7. First head-to-head trials of once weekly Fosamax and Actonel therapies
8. Hormone Replacement Therapy increases the risk of endometrial cancer
9. Atrial fibrillation predicts for acute ischaemic stroke
10. Spray on contraceptive clears Phase I trial
11. The Indian Government has given the nod to conduct Human volunteer trials inorder to develop preventive AIDS vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... The Advocator Group, LLC is ... Foundation for Suicide Prevention’s (AFSP) Out of the Darkness ... organization that hosts hundreds of community walks throughout the ... used to help understand and prevent suicide through not ... well. , The Advocator Group shares this passion ...
(Date:10/20/2014)... 2014 Women’s health specialist, Dr. Amber ... Gynecology of Columbus, Inc., A Division of MaternOhio Clinical ... more than 100,000 patients annually. Dr. Murphy will provide ... stages of a women’s life. She is accepting new ... Westerville and Dublin. , Dr. Murphy offers a wide ...
(Date:10/20/2014)... Indianapolis, IN (PRWEB) October 20, 2014 ... Quick Start, a secure cloud solution that enables ... advantage of the ultimate healthcare-specific customer relationship management ... to meet the unique needs of the healthcare ... healthcare experience for providers and patients by combining ...
(Date:10/20/2014)... JZ Fitness, an independently operated wellness ... programming, authorship, international lecturing and community wellness, created by ... release of the JZ Fitness nutrition app, available on ... thousands of individuals on nutrition, Jenn Zerling (“JZ”) has ... require calorie counting or cumbersome food logging. ...
(Date:10/20/2014)... Principle Business Enterprises, a family owned ... top-of-the-line absorbent products. The company has recently made ... brand, Tranquility® Premium Protection absorbent products. The company ... its packaging a new look, and is currently working ... the public. , The new website, developed with Thread ...
Breaking Medicine News(10 mins):Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2
... University School of Optometry researcher,s ongoing work to improve ... leading causes of blindness will advance with support from ... Health. IU School of Optometry Professor William H. ... patient studies at optometry clinics in Bloomington, Indianapolis and ...
... doubled in young children, study finds , THURSDAY, Jan. ... vaccine for bacterial pneumonia was introduced in the United ... pneumonia because of pneumococcus has decreased by 50 percent ... , But the scientists also found a 70 percent ...
... ... of the devastating earthquake that struck Haiti yesterday. , ... (PRWEB) January 14, 2010 -- The ... highlight the urgent need that the Haitian people have for medical care, housing, and ...
... 7 , 2010 in the World Journal of ... clinical trial, the authors examined if acupuncture could prevent ... with colon cancer in Shanghai, China. Acupuncture did not ... who developed PPOI also suggested acupuncture was not useful ...
... we experience, which have no tangible existence, arise out ... the Weizmann Institute of Science provided evidence, for the ... underlies the experience of seeing. In research recently ... Malach and research student Lior Fisch of the Weizmann ...
... , THURSDAY, Jan. 14 (HealthDay News) -- One of ... therapy on the risk of stroke confirms the benefits ... benefit from statins such as Crestor, Lipitor and Zocor ... of "bad" LDL cholesterol, the researchers found. , Data ...
Cached Medicine News:Health News:Refinement of glaucoma testing, treatment expected from US, United Kingdom study 2Health News:Refinement of glaucoma testing, treatment expected from US, United Kingdom study 3Health News:Lung Infection Up in Wake of Kids' Pneumonia Vaccine 2Health News:Haiti Foundation Against Poverty Launches New Fundraising Drive to Help Victims of Earthquake 2Health News:Does electro-acupuncture prevent prolonged postoperative ileus? 2Health News:To see or not to see 2Health News:More Evidence That Statins Cut Stroke Risk 2Health News:More Evidence That Statins Cut Stroke Risk 3
(Date:10/17/2014)... , October 17, 2014 ... http://www.researchandmarkets.com/research/7jx6nq/china ) has announced the addition of ...  report to their offering.       ... cardiovascular disease in China ... and changes in consumption concept, dietary habit, ...
(Date:10/17/2014)... Investor-Edge has initiated coverage on ... ARNA ), NPS Pharmaceuticals Inc. (NASDAQ: NPSP ... Pharmaceuticals Inc. (NASDAQ: MNTA ), and Catalyst ... five companies can be accessed at: http://investor-edge.com/register ... 2014, ended on a mixed note as the Dow ...
(Date:10/17/2014)... 17, 2014  Ameritox SM , the nation,s leader ... Thomas Smith , M.D., as Chief Medical Officer. ... offering scientific resources for healthcare providers, patients and managed ... positions at a variety of healthcare companies that have ... pain and behavioral health sides of Ameritox,s business. He ...
Breaking Medicine Technology:China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Ameritox Appoints New Chief Medical Officer 2
... Host a Workshop on... -- CRAIGAVON, Northern Ireland, November 19, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
... Inc., a worldwide leader in surgical care, announced today ... (BLA) to the U.S. Food and Drug Administration (FDA) ... combines Ethicon,s biomaterials and plasma-derived biologics (Human Fibrinogen and ... during surgery. "Excessive bleeding during surgical procedures ...
Cached Medicine Technology:Almac and the Royal Society of Chemistry Host a Workshop on the use of Analytical Techniques to Control and Monitor Solid Form 2Almac and the Royal Society of Chemistry Host a Workshop on the use of Analytical Techniques to Control and Monitor Solid Form 3Almac and the Royal Society of Chemistry Host a Workshop on the use of Analytical Techniques to Control and Monitor Solid Form 4Almac and the Royal Society of Chemistry Host a Workshop on the use of Analytical Techniques to Control and Monitor Solid Form 5Almac and the Royal Society of Chemistry Host a Workshop on the use of Analytical Techniques to Control and Monitor Solid Form 6Almac and the Royal Society of Chemistry Host a Workshop on the use of Analytical Techniques to Control and Monitor Solid Form 7Almac and the Royal Society of Chemistry Host a Workshop on the use of Analytical Techniques to Control and Monitor Solid Form 8Ethicon Submits Biologic License Application to the FDA for the Fibrin Pad 2Ethicon Submits Biologic License Application to the FDA for the Fibrin Pad 3
This is a single-action instrument that features a spring handle....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
Medicine Products: